Combined General Meeting of 1 June 2012

This article or press release has no online content. Please download the associated documents for more information.

Statement on IRLAB’s mesdopetam Phase IIb trial results

J.P. Morgan Conference 2023: Ipsen shares strategy success

Living with PBC: The Person Behind the Chart

A Life in a Day of an FOP person: from Empathy to Understanding…

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2023